Viking Therapeutics reports Q4 EPS (25c), consensus (25c)

As of the end of Q4 and year ended December 31, 2023, the company held approximately $362M in cash, cash equivalents, and marketable securities. “2023 was an event-filled year for Viking, with the company achieving significant progress with each of our four clinical programs,” stated Brian Lian, CEO. “…We expect to report topline results from both the VENTURE Phase 2 study and the Phase 1 trial of oral VK2735 in 1Q24. An additional highlight for 2023 was the announcement of positive topline results from our Phase 2b VOYAGE study of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis with fibrosis. This study affirmed VK2809’s best-in-class profile, demonstrating statistically significant liver-fat reduction, unique lipid-lowering properties, and favorable safety and tolerability profile. We look forward to reporting the 52-week biopsy data from this study in the first half of 2024. Importantly, we completed 2023 with a strong cash position that will support our objectives for 2024 and beyond.”